[{"notes_id":"1_1692","category":"3","subcategory":"1","title":"Diabetes mellitus: management of type 2","body":"NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022. This update reflected the advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors.<br \/><br \/><div class='alert alert-warning'>It's worthwhile thinking of the average patient who is taking metformin for T2DM, you can titrate up metformin and encourage lifestyle changes to aim for a HbA1c of <span class=\"concept\" data-cid=\"9108\">48 mmol\/mol<\/span> (6.5%), but should only add a second drug if the HbA1c rises to <span class=\"concept\" data-cid=\"9109\">58 mmol\/mol<\/span> (7.5%)<br \/><\/div><br \/><br \/>Dietary advice<br \/><ul><li>encourage high fibre, low glycaemic index sources of carbohydrates<\/li><li>include low-fat dairy products and oily fish<\/li><li>control the intake of foods containing saturated fats and trans fatty acids<\/li><li>limited substitution of sucrose-containing foods for other carbohydrates is allowable, but care should be taken to avoid excess energy intake<\/li><li>discourage the use of foods marketed specifically at people with diabetes<\/li><li>initial target weight loss in an overweight person is 5-10%<\/li><\/ul><br \/><br \/><h5 class='notes-heading'>HbA1c targets<\/h5><br \/>This is an area which has changed in 2015<br \/><ul><li>individual targets should be agreed with patients to encourage motivation<\/li><li>HbA1c should be checked every 3-6 months until stable, then 6 monthly<\/li><li>NICE encourage us to consider relaxing targets on <i>'a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes'<\/i><\/li><li>in 2015 the guidelines changed so HbA1c targets are now dependent on treatment:<\/li><\/ul><br \/><h6 class='notes-subheading'>Lifestyle or single-drug treatment<\/h6><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Management of T2DM<\/th><th>HbA1c target<\/th><\/tr><\/thead><tbody><tr><td>Lifestyle<\/td><td><span class=\"concept\" data-cid=\"9108\">48 mmol\/mol<\/span> (6.5%)<\/td><\/tr><tr><td>Lifestyle + metformin<\/td><td><span class=\"concept\" data-cid=\"9108\">48 mmol\/mol<\/span> (6.5%)<\/td><\/tr><tr><td>Includes any drug which may cause hypoglycaemia (e.g. lifestyle + sulfonylurea)<\/td><td>53 mmol\/mol (7.0%)<\/td><\/tr><\/tbody><\/table><\/div><br \/>Practical examples<br \/><ul><li>a patient is newly diagnosed with HbA1c and wants to try lifestyle treatment first. You agree on a target of 48 mmol\/mol (6.5%)<\/li><li>you review a patient 6 months after starting metformin. His HbA1c is 51 mmol\/mol (6.8%). You increase his metformin from 500mg bd to 500mg tds and reinforce lifestyle factors<\/li><\/ul><br \/><h6 class='notes-subheading'>Patient already on treatment<\/h6><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid2\" ><thead><tr><th>Management of T2DM<\/th><th>HbA1c target<\/th><\/tr><\/thead><tbody><tr><td>Already on one drug, but HbA1c has risen to <span class=\"concept\" data-cid=\"9109\">58 mmol\/mol<\/span> (7.5%)<\/td><td>53 mmol\/mol (7.0%)<\/td><\/tr><\/tbody><\/table><\/div><br \/><h5 class='notes-heading'>Initial drug therapy<\/h5><br \/><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd928b.png'><img class='ajaximage' src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd928.png'\/><\/a><\/td><\/tr><tr><td valign='top' align='left'><\/td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd928b.png'><img src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/mag_glass.png'\/><\/a><\/td><\/tr><\/table><\/CENTER><div class='imagetext'>Simplified initial management of type 2 diabetes mellitus<\/div><br \/><span class=\"concept\" data-cid=\"9107\">Metformin remains the first-line drug<\/span> of choice in type 2 diabetes mellitus.<br \/><ul><li>metformin should be titrated up slowly to minimise the possibility of gastrointestinal upset<\/li><li>if standard-release metformin is not tolerated then modified-release metformin should be trialled<\/li><\/ul><br \/><span class=\"concept\" data-cid=\"11772\">SGLT-2 inhibitors<\/span><br \/><ul><li>should also be given in addition to metformin if any of the following apply:<ul><li>the patient has a high risk of developing cardiovascular disease (CVD, e.g. QRISK \u2265 10%)<\/li><li>the patient has established CVD<\/li><li>the patient has chronic heart failure<\/li><\/ul><\/li><li><span class=\"concept\" data-cid=\"11773\">metformin should be established and titrated up before introducing the SGLT-2 inhibitor<\/span><\/li><li><span class=\"concept\" data-cid=\"11774\">SGLT-2 inhibitors should also be started at any point if a patient develops CVD (e.g. is diagnosed with ischaemic heart disease), a QRISK \u2265 10% or chronic heart failure<\/span><\/li><\/ul><br \/>If metformin is contraindicated<br \/><ul><li>if the patient has a risk of CVD, established CVD or chronic heart failure:<ul><li><span class=\"concept\" data-cid=\"11775\">SGLT-2 monotherapy<\/span><\/li><\/ul><\/li><li>if the patient doesn't have a risk of CVD, established CVD or chronic heart failure:<ul><li><span class=\"concept\" data-cid=\"11776\">DPP-4 inhibitor or pioglitazone or a sulfonylurea<\/span><\/li><li>SGLT-2 may be used if certain NICE criteria are met<\/li><\/ul><\/li><\/ul><br \/><br \/><h5 class='notes-heading'>Further drug therapy if HbA1c targets are not met<\/h5><br \/><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd929b.png'><img class='ajaximage' src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd929.png'\/><\/a><\/td><\/tr><tr><td valign='top' align='left'><\/td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd929b.png'><img src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/mag_glass.png'\/><\/a><\/td><\/tr><\/table><\/CENTER><div class='imagetext'>Simplified further management of type 2 diabetes mellitus if HbA1c targets are not met<\/div><br \/>If the HbA1c has risen to 58 mmol\/mol (7.5%) then further treatment is indicated. Given the large number of drug therapy options, medication choices depend on individual clinical circumstances (comorbidities, contraindications, weight) and patient preference.<br \/><br \/><h6 class='notes-subheading'>Second-line therapy<\/h6><br \/><span class=\"concept\" data-cid=\"11777\">Dual therapy - add one of the following:<\/span><br \/><ul><li>metformin + DPP-4 inhibitor<\/li><li>metformin + pioglitazone<\/li><li>metformin + sulfonylurea<\/li><li>metformin + SGLT-2 inhibitor (if NICE criteria met)<\/li><\/ul><br \/><h6 class='notes-subheading'>Third-line therapy<\/h6><br \/><span class=\"concept\" data-cid=\"11395\">If a patient does not achieve control on dual therapy then the following options are possible:<\/span><br \/><ul><li>metformin + DPP-4 inhibitor + sulfonylurea<\/li><li>metformin  + pioglitazone + sulfonylurea<\/li><li>metformin + (pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGLT-2 if certain NICE criteria are met<\/li><li>insulin-based treatment<\/li><\/ul><br \/><h6 class='notes-subheading'>Further therapy<\/h6><br \/>If triple therapy is not effective or tolerated consider <span class=\"concept\" data-cid=\"11396\">switching one of the drugs for a GLP-1 mimetic<\/span>:<br \/><ul><li>BMI \u2265 35 kg\/m\u00b2 and specific psychological or other medical problems associated with obesity or<\/li><li>BMI < 35 kg\/m\u00b2 and for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities<\/li><li>only continue if there is a reduction of at least 11 mmol\/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months<\/li><\/ul><br \/>GLP-1 mimetics should only be added to insulin under specialist care<br \/><br \/>Starting insulin<br \/><ul><li>metformin should be continued. In terms of other drugs NICE advice: <i>'Review the continued need for other blood glucose-lowering therapies'<\/i><\/li><li>NICE recommend starting with human NPH insulin (isophane, intermediate-acting) taken at bed-time or twice daily according to need<\/li><\/ul><br \/>Practical examples<br \/><ul><li>you review an established type 2 diabetic on maximum dose metformin. Her HbA1c is 55 mmol\/mol (7.2%). You do not add another drug as she has not reached the threshold of 58 mmol\/mol (7.5%)<\/li><li>a type 2 diabetic is found to have an HbA1c of 62 mmol\/mol (7.8%) at annual review. They are currently on maximum dose metformin. You elect to add a sulfonylurea<\/li><\/ul><br \/><br \/><h5 class='notes-heading'>Risk factor modification<\/h5><br \/>Hypertension<br \/><ul><li><span class=\"concept\" data-cid=\"399\"><b>blood pressure targets are the same as for patients without type 2 diabetes<\/b> (see table below)<\/span><\/li><li>ACE inhibitors or angiotensin II receptor blockers (ARB) are first-line<ul><li>an <span class=\"concept\" data-cid=\"11206\">ARB is preferred if the patient has a black African or African-Caribbean<\/span> family origin<\/li><\/ul><\/li><\/ul><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid3\" ><thead><tr><th><\/th><th><b>Clinic BP<\/b><\/th><th><b>ABPM \/ HBPM<\/b><\/th><\/tr><\/thead><tbody><tr><td><b>Age < 80 years<\/b><\/td><td>140\/90 mmHg<\/td><td>135\/85 mmHg<\/td><\/tr><tr><td><b>Age > 80 years<\/b><\/td><td>150\/90 mmHg<\/td><td>145\/85 mmHg<\/td><\/tr><\/tbody><\/table><\/div><br \/>Antiplatelets<br \/><ul><li>should not be offered unless a patient has existing cardiovascular disease<\/li><\/ul><br \/>Lipids<br \/><ul><li>following the 2014 NICE lipid modification guidelines only patients with a 10-year cardiovascular risk > 10% (using QRISK2) should be offered a statin. The first-line statin of choice is atorvastatin 20mg on<\/li><\/ul><br \/><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd915b.png'><img class='ajaximage' src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd915.png'\/><\/a><\/td><\/tr><tr><td valign='top' align='left'><\/td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd915b.png'><img src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/mag_glass.png'\/><\/a><\/td><\/tr><\/table><\/CENTER><div class='imagetext'>Graphic showing choice of statin.<\/div>","notes_hash":"ca06d8c38ddc0f626be19075164b9bce","knowledge_graph_node_id_link":10924,"links":"<table style='width:100%'><tr><td>SIGN<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_721\" data-linkid=\"721\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_721\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">36<\/span><button type=\"button\" style=\"\" id=\"link_dislike_721\" data-linkid=\"721\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_721\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">47<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.sign.ac.uk\/assets\/qrg116.pdf\">2010 Management of diabetes<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_457\" data-linkid=\"457\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_457\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">34<\/span><button type=\"button\" style=\"\" id=\"link_dislike_457\" data-linkid=\"457\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_457\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">43<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/CG181\/chapter\/1-Recommendations\">2014 Lipid modification guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_911\" data-linkid=\"911\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_911\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">56<\/span><button type=\"button\" style=\"\" id=\"link_dislike_911\" data-linkid=\"911\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_911\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">54<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations\">2022 Type 2 diabetes guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>7 minute medics<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1395\" data-linkid=\"1395\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1395\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">44<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1395\" data-linkid=\"1395\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1395\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">32<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/anchor.fm\/7minutemedics\/episodes\/Episode-2---Type-2-Diabetes-e2ebql\">Basics of type 2 diabetes - podcast<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"51\" data-downvotes=\"6\" data-media=\"694\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/4Y7wdX7iEAY\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"51\" data-downvotes=\"6\" data-media=\"694\">Type 2 diabetes agents and their mechanism of action<\/a><\/td><\/tr><tr><td><span ><small>Brandl's Basics - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1195\" data-mediaid=\"1195\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1195\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">51<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1195\" data-mediaid=\"1195\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1195\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">6<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"9\" data-downvotes=\"6\" data-media=\"693\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/APHeDOkJKQ0\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"9\" data-downvotes=\"6\" data-media=\"693\"> Pharmacology of drugs used to treat type 2 diabetes<\/a><\/td><\/tr><tr><td><span ><small>Brandl's Basics - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1194\" data-mediaid=\"1194\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1194\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">9<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1194\" data-mediaid=\"1194\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1194\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">6<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/W0KPwTy0W9k\" data-description=\"Diabetes Type II Pathophysiology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"400\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/W0KPwTy0W9k\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/W0KPwTy0W9k\" data-description=\"Diabetes Type II Pathophysiology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"400\">Diabetes Type II Pathophysiology<\/a><\/td><\/tr><tr><td><span ><small>Armando Hasudungan - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_685\" data-mediaid=\"685\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_685\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4<\/span><button type=\"button\" style=\"\" id=\"media_dislike_685\" data-mediaid=\"685\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_685\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"9108":{"concept_text":"The standard HbA1c target in type 2 diabetes mellitus is 48 mmol\/mol","concept_percentile":"81"},"11395":{"concept_text":"TD2M already on 2 drugs - if HbA1c > 58 mmol\/mol then one of the following should be offered:\n   - metformin + DPP-4 inhibitor + sulfonylurea\n   - metformin  + pioglitazone + sulfonylurea\n   - metformin + (pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGLT-2 if certain NICE criteria are met\n   - insulin-based treatment","concept_percentile":"73"},"11396":{"concept_text":"TD2M: if a triple combination of drugs has failed to reduce HbA1c then switching one of the drugs for a GLP-1 mimetic is recommended, particularly if the BMI > 35","concept_percentile":"76"},"11772":{"concept_text":"SGLT-2 inhibitors should be used in addition to metformin as initial therapy for T2DM if CVD, high-risk of CVD or chronic heart failure","concept_percentile":"65"},"11773":{"concept_text":"If starting an SGLT-2 as initial therapy for T2DM then ensure metformin is titrated up first","concept_percentile":"91"},"11774":{"concept_text":"In patients with T2DM, SGLT-2 should be introduced at any point they develop CVD, a high risk of CVD or chronic heart failure","concept_percentile":"66"},"11775":{"concept_text":"T2DM initial therapy: if metformin is contraindicated + patient has a risk of CVD, established CVD or chronic heart failure --> SGLT-2 monotherapy","concept_percentile":"88"},"11776":{"concept_text":"T2DM initial therapy: if metformin is contraindicated (and no risk of CVD, established CVD or chronic heart failure) --> choice of DPP-4 inhibitor or Pioglitazone or Sulfonylurea or even SGLT-2 (if NICE criteria met)","concept_percentile":"89"},"11777":{"concept_text":"T2DM on metformin, if HbA1c has risen to 58 mmol\/mol then one of the following should be offered depending on the individual clinical scenario:\n   - DPP-4 inhibitor\n   - pioglitazone\n   - sulfonylurea\n   - SGLT-2 inhibitor (if NICE criteria met)","concept_percentile":"74"}},"category_name":"Endocrinology \/ Metabolic","subcategory_name":"Endocrinology","comment_count":24},"",[]]